Sort
40,608 grants matching “prostate cancer”
Photodynamic Therapy - Basic Science Studies
$754,688Healthone Alliance · P01 · FY2004 · CA
Arkansas Cancer Community Network (ARCCN)
$754,664Ronda S Henry-Tillman · Univ Of Arkansas For Med Scis · U01 · FY2009 · CA
Transcriptional heterogeneity and regulatory mechanisms in tumor microenvironment
$754,604Sridhar Hannenhalli · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
A Phase II trial of abiraterone in combination with PDMX1001 in enzalutamide-resistant prostate cancer
$754,319Chengfei Liu · Pandomedx, Inc. · R44 · FY2018 · CA
SHCC MU NCORP
$754,181Thomas Lad · Hektoen Institute For Medical Research · UG1 · FY2018 · CA
Inflammation and Colorectal Neoplasia
$754,094Andrew T Chan · Massachusetts General Hospital · R01 · FY2016 · CA
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
$753,745Rajesh Krishnan · Oncternal Therapeutics, Inc. · R44 · FY2023 · NS
Epigenetic Regulation of Normal and Pathologic CTCF Functions by BORIS
$753,460Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent
$753,394Charite Nicolette Ricker · University Of Southern California · R01 · FY2024 · CA
Elucidation of cancer pathways and druggable targets using mouse models.
$753,359Cory Abate-Shen · Columbia University Health Sciences · U01 · FY2012 · CA
CD44 PLAYS AN ESSENTIAL ROLE IN PROMOTING METASTASIS AND CHEMORESISTANCE OF PROSTATE CANCER CELLS AND IS A PRIME THERAPEUTIC TARGET
$753,120Icahn School Of Medicine At Mount Sinai · · FY2010 · Department of the Army
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (3 of 3)
$753,044Baqar A Husaini · Tennessee State University · U54 · FY2012 · CA
A Multimodal Imaging System and Targeted Nanoprobes for Image-Guided Treatment of Breast Cancer
$752,876Huabei Jiang · University Of Florida · R01 · FY2016 · EB
A Clinical Validation Center for Early Detection of Pancreatic Cancer
$752,866Anirban Maitra · University Of Tx Md Anderson Can Ctr · U01 · FY2020 · CA
TRANSGENIC MOUSE MODELS OF PROSTATE CANCER
$752,750Baylor College Of Medicine · U01 · FY2003 · CA
Characterization of Cancer Stem Cells
$752,616William Farrar · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Molecular Mechanisms of Growth Factor Modulated Proliferation
$752,616William Farrar · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
DISCOVERY AND DEVELOPMENT OF MITHRAMYCIN ANALOGS FOR PROSTATE CANCER TREATMENT BY DIRECT INHIBITION OF THE ONCOGENIC TRANSCRIPTION FACTOR ERG (TMPRSS
$752,500University Of Kentucky Research Foundation, The · · FY2016 · Department of the Army
Molecular, Cellular, and Tissue Characterization Unit
$752,398Joe W. Gray · Oregon Health & Science University · U2C · FY2022 · CA
TARGETING THE ADIPOCYTE-TUMOR CELL INTERACTION IN PROSTATE CANCER TREATMENT 13-1-0353 IS PART OF A COLLABORATIVE EFFORT WITH 13-1-0354
$751,903Sanford Burnham Prebys Medical Discovery Institute · · FY2013 · Department of Defense
MS/AL Radiation Oncology Research Partnership
$751,371Wiley Sam Dennis · Singing River Health System · U56 · FY2006 · CA
[PQC-3] A Metabolic Pathway Activation Marker for Prostate Cancer Prognosis
$751,274Hirak S. Basu · University Of Wisconsin-Madison · R01 · FY2014 · CA
Randomized trial of community health worker-led decision coaching to promote shared decision making for prostate cancer screening among Black male patients and their providers
$751,264Danil V. Makarov · New York University School Of Medicine · R01 · FY2019 · MD
Role of Neurotrophins in the Development of the Mammalian Nervous System
$751,233Lino Tessarollo · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
DISCOVERY AND DEVELOPMENT OF MITHRAMYCIN ANALOGS FOR PROSTATE CANCER TREATMENT BY DIRECT INHIBITION OF THE ONCOGENIC TRANSCRIPTION FACTOR ERG (TMPRSS
$751,034University Of Kentucky Research Foundation, The · · FY2016 · Department of the Army